These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16769090)

  • 1. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.
    Siuciak JA; McCarthy SA; Chapin DS; Fujiwara RA; James LC; Williams RD; Stock JL; McNeish JD; Strick CA; Menniti FS; Schmidt CJ
    Neuropharmacology; 2006 Aug; 51(2):374-85. PubMed ID: 16769090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme.
    Siuciak JA; McCarthy SA; Chapin DS; Reed TM; Vorhees CV; Repaske DR
    Neuropharmacology; 2007 Jul; 53(1):113-24. PubMed ID: 17559891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background.
    Siuciak JA; McCarthy SA; Chapin DS; Martin AN; Harms JF; Schmidt CJ
    Neuropharmacology; 2008 Feb; 54(2):417-27. PubMed ID: 18061215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
    Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
    Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Eur Neuropsychopharmacol; 2008 May; 18(5):339-63. PubMed ID: 17913473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired appetitively as well as aversively motivated behaviors and learning in PDE10A-deficient mice suggest a role for striatal signaling in evaluative salience attribution.
    Piccart E; Gantois I; Laeremans A; de Hoogt R; Meert T; Vanhoof G; Arckens L; D'Hooge R
    Neurobiol Learn Mem; 2011 Mar; 95(3):260-9. PubMed ID: 21130175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice.
    Ehrman LA; Williams MT; Schaefer TL; Gudelsky GA; Reed TM; Fienberg AA; Greengard P; Vorhees CV
    Genes Brain Behav; 2006 Oct; 5(7):540-51. PubMed ID: 17010100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.
    Strick CA; James LC; Fox CB; Seeger TF; Menniti FS; Schmidt CJ
    Neuropharmacology; 2010 Feb; 58(2):444-51. PubMed ID: 19765598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2.
    Sano H; Nagai Y; Miyakawa T; Shigemoto R; Yokoi M
    J Neurochem; 2008 Apr; 105(2):546-56. PubMed ID: 18088367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs.
    Yee BK; Singer P; Chen JF; Feldon J; Boison D
    Eur J Neurosci; 2007 Dec; 26(11):3237-52. PubMed ID: 18005073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
    Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
    Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
    Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
    J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
    Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
    Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
    Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic deletion of PDE10A selectively impairs incentive salience attribution and decreases medium spiny neuron excitability.
    Piccart E; De Backer JF; Gall D; Lambot L; Raes A; Vanhoof G; Schiffmann S; D'Hooge R
    Behav Brain Res; 2014 Jul; 268():48-54. PubMed ID: 24698799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
    Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
    J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-pubertal emergence of alterations in locomotor activity in stop null mice.
    Bégou M; Brun P; Bertrand JB; Job D; Schweitzer A; D'Amato T; Saoud M; Andrieux A; Suaud-Chagny MF
    Synapse; 2007 Sep; 61(9):689-97. PubMed ID: 17559095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons.
    Sotty F; Montezinho LP; Steiniger-Brach B; Nielsen J
    J Neurochem; 2009 May; 109(3):766-75. PubMed ID: 19236563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine.
    Dall'Igna OP; Hoffmann A; da Silva AL; Souza DO; Lara DR
    Neurodegener Dis; 2004; 1(1):38-43. PubMed ID: 16908972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wfs1-deficient mice display impaired behavioural adaptation in stressful environment.
    Luuk H; Plaas M; Raud S; Innos J; Sütt S; Lasner H; Abramov U; Kurrikoff K; Kõks S; Vasar E
    Behav Brain Res; 2009 Mar; 198(2):334-45. PubMed ID: 19041897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.